Clinical Trial Update: Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether osimertinib can suppress progression of ground-glass nodules in EGFR mutation-positive lung cancer, currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING